Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Regen BioPharma (RGBP) over the last 12 years, with Q4 2025 value amounting to -$197941.0.

  • Regen BioPharma's Cash from Operations fell 19819.82% to -$197941.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$515153.0, marking a year-over-year increase of 2142.01%. This contributed to the annual value of -$383591.0 for FY2025, which is 4895.91% up from last year.
  • Regen BioPharma's Cash from Operations amounted to -$197941.0 in Q4 2025, which was down 19819.82% from -$160005.0 recorded in Q3 2025.
  • Regen BioPharma's 5-year Cash from Operations high stood at -$10463.0 for Q4 2022, and its period low was -$1.1 million during Q3 2021.
  • For the 5-year period, Regen BioPharma's Cash from Operations averaged around -$170781.3, with its median value being -$118818.0 (2022).
  • As far as peak fluctuations go, Regen BioPharma's Cash from Operations skyrocketed by 9625.16% in 2022, and later plummeted by 145152.44% in 2023.
  • Over the past 5 years, Regen BioPharma's Cash from Operations (Quarter) stood at -$279135.0 in 2021, then surged by 96.25% to -$10463.0 in 2022, then plummeted by 1451.52% to -$162336.0 in 2023, then surged by 59.11% to -$66379.0 in 2024, then tumbled by 198.2% to -$197941.0 in 2025.
  • Its last three reported values are -$197941.0 in Q4 2025, -$160005.0 for Q3 2025, and -$55977.0 during Q2 2025.